Tafenoquine: a toxicity overview.
Tafenoquine: a toxicity overview.
复制标题
他非诺喹：毒性概述。
DOI：
10.1080/14740338.2021.1859476
复制
发表时间：
2021-03
影响因子：
3.1
通讯作者：
Hwang, Jimee
中科院分区：
文献类型：
--
作者：
Chu, Cindy S.;Hwang, Jimee
关键词：
8-氨基喹啉是唯一预防疟疾复发的抗疟疾药物类别，其长达一个世纪的历史已导致美国食品和药物管理局（FDA）和澳大利亚治疗用品管理局（TGA）批准了他非诺喹，并在巴西和泰国注册。他非诺喹是间日疟和疟疾预防的抗复发替代疗法。妊娠期、哺乳期、葡萄糖-6-磷酸脱氢酶（G6 PD）未知或缺乏状态的婴儿以及G6 PD缺乏症或精神疾病患者不应给予本品。本系统性综述评估了他非诺喹在英语人体临床试验中的相关不良事件。对常见不良事件进行荟萃分析，并按比较组进行分组。他非诺喹，无论是根治或预防，通常是良好的耐受性在成人。没有令人信服的神经、眼科和心脏毒性证据。归因于较高剂量的精神障碍是化学预防适应症的禁忌症，精神疾病是根治适应症的警告。需要进行妊娠评估和定量G6 PD检测。最佳的根治性治疗方案，包括他非诺喹剂量沿着其安全性，东南亚，南美洲和大洋洲的部分地区需要进一步评估。
A century-long history in 8-aminoquinolines, the only anti-malaria drug class preventing malaria relapse, has resulted in the approval of tafenoquine by the U.S. Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) and to date registration in Brazil and Thailand. Tafenoquine is an alternative anti-relapse treatment for vivax malaria and malaria prophylaxis. It should not be given in pregnancy, during lactation of infants with glucose-6-phosphate dehydrogenase (G6PD) unknown or deficient status, and in those with G6PD deficiency or psychiatric illness. This systematic review assesses tafenoquine associated adverse events in English-language, human clinical trials. Meta-analysis of commonly reported adverse events was conducted and grouped by comparison arms. Tafenoquine, either for radical cure or prophylaxis, is generally well tolerated in adults. There is no convincing evidence for neurologic, ophthalmic, and cardiac toxicities. Psychotic disorder which has been attributed to higher doses is a contraindication for the chemoprophylaxis indication and psychiatric illness is a warning for the radical cure indication. Pregnancy assessment and quantitative G6PD testing are required. The optimal radical curative regimen including the tafenoquine dose along with its safety for parts of Southeast Asia, South America, and Oceania needs further assessment.
登录
查看更多内容
影响因子：
5.6
作者：
Gómez-Manzo S;Marcial-Quino J;Vanoye-Carlo A;Serrano-Posada H;Ortega-Cuellar D;González-Valdez A;Castillo-Rodríguez RA;Hernández-Ochoa B;Sierra-Palacios E;Rodríguez-Bustamante E;Arreguin-Espinosa R
通讯作者：
Arreguin-Espinosa R
影响因子：
2.9
作者：
Green, Justin A.;Patel, Apurva K.;Miller, Ann K.
通讯作者：
Miller, Ann K.
影响因子：
158.5
作者：
COHEN, RJ;SACHS, JR;CONRAD, ME
通讯作者：
CONRAD, ME
影响因子：
11.8
作者：
Hale, BR;Owusu-Agyei, S;Hoffman, SL
通讯作者：
Hoffman, SL
影响因子：
3.4
作者：
Edstein, MD;Kocisko, DA;Charles, BG
通讯作者：
Charles, BG